Regulatory macrophages as therapeutic targets and therapeutic agents in solid organ transplantation

Current Opinion in Organ Transplantation

Volumn 17, Issue 4, 2012, Pages 332-342

  Broichhausen, Christiane ^a   Riquelme, Paloma ^a   Geissler, Edward K ^a   Hutchinson, James A ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

cell based medicinal product; M reg; regulatory macrophage; the ONE study

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 1BETA; LOSARTAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ACUTE GRAFT REJECTION; ADAPTIVE IMMUNITY; CELL DIFFERENTIATION; CELL MATURATION; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE ACTIVATION; MESENCHYMAL STEM CELL; MONOCYTE; NONHUMAN; ORGAN TRANSPLANTATION; PHAGOCYTOSIS; PROTEIN EXPRESSION; REPERFUSION INJURY; REVIEW;

GRAFT REJECTION; HUMANS; MACROPHAGES; ORGAN TRANSPLANTATION; REPERFUSION INJURY; TISSUE THERAPY; TRANSPLANTATION TOLERANCE;

EID: 84863852907     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e328355a979     Document Type: Review

References (113)

1. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005; 5:953-964.
2. Geissmann F, Gordon S, Hume DA, et al. Unravelling mononuclear phagocyte heterogeneity. Nat Rev Immunol 2010; 10:453-460.
3. Hume DA. Macrophages as APC and the dendritic cell myth. J Immunol 2008; 181:5829-5835.
4. Mannon RB. Macrophages: contributors to allograft dysfunction, repair, or innocent bystanders? Curr Opin Organ Transplant 2012; 17:20-25.
5. Hutchinson JA, Riquelme P, Sawitzki B, et al. Cutting edge: immunological consequences and trafficking of human regulatory macrophages administered to renal transplant recipients. J Immunol 2011; 187:2072-2078.
6. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 2011; 11:723-737.
7. Hashimoto D, Miller J, Merad M. Dendritic cell and macrophage heterogeneity in vivo. Immunity 2011; 35:323-335.
8. Hume DA, Ross IL, Himes SR, et al. The mononuclear phagocyte system revisited. J Leukoc Biol 2002; 72:621-627.
9. Stout RD, Suttles J. Functional plasticity of macrophages: reversible adaptation to changing microenvironments. J Leukoc Biol 2004; 76:509-513.
10. Martinez FO, Gordon S, Locati M, Mantovani A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol 2006; 177:7303-7311.
11. Taylor PR, Martinez-Pomares L, Stacey M, et al. Macrophage receptors and immune recognition. Annu Rev Immunol 2005; 23:901-944.
12. Gordon S. The macrophage: past, present and future. Eur J Immunol 2007; 37 (Suppl 1):S9-S17.
13. Pluddemann A, Mukhopadhyay S, Gordon S. Innate immunity to intracellular pathogens: macrophage receptors and responses to microbial entry. Immunol Rev 2011; 240:11-24.
14. Pozzi LA, Maciaszek JW, Rock KL. Both dendritic cells and macrophages can stimulate naive CD8 T cells in vivo to proliferate, develop effector function, and differentiate into memory cells. J Immunol 2005; 175:2071-2081.
15. Pizzolla A, Gelderman KA, Hultqvist M, et al. CD68-expressing cells can prime T cells and initiate autoimmune arthritis in the absence of reactive oxygen species. Eur J Immunol 2011; 41:403-412.
16. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 2010; 11:889-896.
17. Anders HJ, Ryu M. Renal microenvironments and macrophage phenotypes determine progression or resolution of renal inflammation and fibrosis. Kidney Int 2011; 80:915-925.
18. Lucas T, Waisman A, Ranjan R, et al. Differential roles of macrophages in diverse phases of skin repair. J Immunol 2010; 184:3964-3977.
19. Brancato SK, Albina JE. Wound macrophages as key regulators of repair: origin, phenotype, and function. Am J Pathol 2011; 178:19-25.
20. Passlick B, Flieger D, Ziegler-Heitbrock HW. Identification and characterization of a novel monocyte subpopulation in human peripheral blood. Blood 1989; 74:2527-2534.
21. Grage-Griebenow E, Flad HD, Ernst M. Heterogeneity of human peripheral blood monocyte subsets. J Leukoc Biol 2001; 69:11-20.
22. Grage-Griebenow E, Zawatzky R, Kahlert H, et al. Identification of a novel dendritic cell-like subset of CD64(-) /CD16(-) blood monocytes. Eur J Immunol 2001; 31:48-56.
23. Randolph GJ, Sanchez-Schmitz G, Liebman RM, Schakel K. The CD16(-) (FcgammaRIII(-)) subset of human monocytes preferentially becomes migratory dendritic cells in a model tissue setting. J Exp Med 2002; 196:517-527.
24. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003; 3:23-35.
25. Mosser DM. The many faces of macrophage activation. J Leukoc Biol 2003; 73:209-212.
26. Bogdan C, Vodovotz Y, Nathan C. Macrophage deactivation by interleukin 10. J Exp Med 1991; 174:1549-1555.
27. Lang R, Patel D, Morris JJ, et al. Shaping gene expression in activated and resting primary macrophages by IL-10. J Immunol 2002; 169:2253-2263.
28. Stout RD, Jiang C, Matta B, et al. Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. J Immunol 2005; 175:342-349.
29. Barnes MJ, Powrie F. Regulatory T cells reinforce intestinal homeostasis. Immunity 2009; 31:401-411.
30. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008; 8:958-969.
31. Gabrilovich DI, Bronte V, Chen SH, et al. The terminology issue for myeloidderived suppressor cells. Cancer Res 2007; 67:425.
32. Dilek N, van RN, Le MA, Vanhove B. Myeloid-derived suppressor cells in transplantation. Curr Opin Organ Transplant 2010; 15:765-768.
33. Lees JR, Azimzadeh AM, Bromberg JS. Myeloid derived suppressor cells in transplantation. Curr Opin Immunol 2011; 23:p692-p627.
34. Schmid M, Wege AK, Ritter U. Characteristics of Tip-DCs and MDSCs and Their Potential Role in Leishmaniasis. Front Microbiol 2012; 3:74.
35. Hume DA, Macdonald KP. Therapeutic applications of macrophage colonystimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood 2012; 119:1810-1820.
36. Doyle AG, Halliday WJ, Barnett CJ, et al. Effect of recombinant human macrophage colony-stimulating factor 1 on immunopathology of experimental brucellosis in mice. Infect Immun 1992; 60:1465-1472.
37. Saraiva M, OGarra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol 2010; 10:170-181.
38. Hammer M, Mages J, Dietrich H, et al. Control of dual-specificity phosphatase-1 expression in activated macrophages by IL-10. Eur J Immunol 2005; 35:2991-3001.
39. OGarra A, Murphy KM. From IL-10 to IL-12: how pathogens and their products stimulate APCs to induce T(H)1 development. Nat Immunol 2009; 10:929-932.
40. Baeke F, Takiishi T, Korf H, et al. Vitamin D: modulator of the immune system. Curr Opin Pharmacol 2010; 10:482-496.
41. Rickard AJ, Young MJ. Corticosteroid receptors, macrophages and cardiovascular disease. J Mol Endocrinol 2009; 42:449-459.
42. Harry RA, Anderson AE, Isaacs JD, Hilkens CM. Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis. Ann Rheum Dis 2010; 69:2042-2050.
43. Brem-Exner BG, Sattler C, Hutchinson JA, et al. Macrophages driven to a novel state of activation have anti-inflammatory properties in mice. J Immunol 2008; 180:335-349.
44. Orabona C, Grohmann U. Indoleamine 2,3-dioxygenase and regulatory function: tryptophan starvation and beyond. Methods Mol Biol 2011; 677:269-280.
45. Mezrich JD, Fechner JH, Zhang X, et al. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol 2010; 185:3190-3198.
46. Munn DH, Zhou M, Attwood JT, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998; 281:1191-1193.
47. Cobbold SP, Adams E, Farquhar CA, et al. Infectious tolerance via the consumption of essential amino acids and mTOR signaling. Proc Natl Acad Sci U S A 2009; 106:12055-12060.
48. Xu X, Yi H, Guo Z, et al. Splenic stroma-educated regulatory dendritic cells induce apoptosis of activated CD4 T cells via Fas ligand-enhanced IFNgamma and nitric oxide. J Immunol 2012; 188:1168-1177.
49. Zhang HG, Su X, Liu D, et al. Induction of specific T cell tolerance by Fas ligand-expressing antigen-presenting cells. J Immunol 1999; 162:1423-1430.
50. Dillon S, Agrawal S, Banerjee K, et al. Yeast zymosan, a stimulus for TLR2 and dectin-1, induces regulatory antigen-presenting cells and immunological tolerance. J Clin Invest 2006; 116:916-928.
51. Mellor AL, Baban B, Chandler PR, et al. Cutting edge: CpG oligonucleotides induce splenic CD19-dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling. J Immunol 2005; 175:5601-5605.
52. Rompaey van N, Moine Le A. Myeloid-derived suppressor cells: characterization and expansion in models of endotoxemia and transplantation. Methods Mol Biol 2011; 677:169-180.
53. Blancou P, Tardif V, Simon T, et al. Immunoregulatory properties of heme oxygenase-1. Methods Mol Biol 2011; 677:247-268.
54. Kalinski P. Regulation of immune responses by prostaglandin E2. J Immunol 2012; 188:21-28.
55. Hutchinson JA, Riquelme P, Geissler EK, Fandrich F. Human regulatory macrophages. Methods Mol Biol 2011; 677:181-192.
56. Li L, Okusa MD. Macrophages, dendritic cells, and kidney ischemia-reperfusion injury. Semin Nephrol 2010; 30:268-277.
57. Bajwa A, Kinsey GR, Okusa MD. Immune mechanisms and novel pharmacological therapies of acute kidney injury. Curr Drug Targets 2009; 10:1196-1204.
58. Jang HR, Rabb H. The innate immune response in ischemic acute kidney injury. Clin Immunol 2009; 130:41-50.
59. Li L, Huang L, Sung SS, et al. The chemokine receptors CCR2 and CX3CR1 mediate monocyte/macrophage trafficking in kidney ischemia-reperfusion injury. Kidney Int 2008; 74:1526-1537.
60. Day YJ, Huang L, Ye H, et al. Renal ischemia-reperfusion injury and adenosine 2A receptor-mediated tissue protection: role of macrophages. Am J Physiol Renal Physiol 2005; 288:F722-F731.
61. Jang HS, Kim J, Park YK, Park KM. Infiltrated macrophages contribute to recovery after ischemic injury but not to ischemic preconditioning in kidneys. Transplantation 2008; 85:447-455.
62. Naidu BV, Krishnadasan B, Farivar AS, et al. Early activation of the alveolar macrophage is critical to the development of lung ischemia-reperfusion injury. J Thorac Cardiovasc Surg 2003; 126:200-207.
63. Nakamura T, bu-Dahab R, Menger MD, et al. Depletion of alveolar macrophages by clodronate-liposomes aggravates ischemia-reperfusion injury of the lung. J Heart Lung Transplant 2005; 24:38-45.
64. Devey L, Ferenbach D, Mohr E, et al. Tissue-resident macrophages protect the liver from ischemia reperfusion injury via a heme oxygenase-1-dependent mechanism. Mol Ther 2009; 17:65-72.
65. Chen Y, Lui VC, Rooijen NV, Tam PK. Depletion of intestinal resident macrophages prevents ischaemia reperfusion injury in gut. Gut 2004; 53:1772-1780.
66. Magil AB. Monocytes/macrophages in renal allograft rejection. Transplant Rev (Orlando) 2009; 23:199-208.
67. Girlanda R, Kleiner DE, Duan Z, et al. Monocyte infiltration and kidney allograft dysfunction during acute rejection. Am J Transplant 2008; 8:600-607.
68. Tinckam KJ, Djurdjev O, Magil AB. Glomerular monocytes predict worse outcomes after acute renal allograft rejection independent of C4d status. Kidney Int 2005; 68:1866-1874.
69. McLean AG, Hughes D, Welsh KI, et al. Patterns of graft infiltration and cytokine gene expression during the first 10 days of kidney transplantation. Transplantation 1997; 63:374-380.
70. Raftery MJ, Seron D, Koffman G, et al. The relevance of induced class II HLA antigens and macrophage infiltration in early renal allograft biopsies. Transplantation 1989; 48:238-243.
71. Hoffmann U, Bergler T, Segerer S, et al. Impact of chemokine receptor CX3CR1 in human renal allograft rejection. Transpl Immunol 2010; 23:204-208.
72. Halloran PF, de Freitas DG, Einecke G, et al. The molecular phenotype of kidney transplants. Am J Transplant 2010; 10:2215-2222.
73. Gao W, Faia KL, Csizmadia V, et al. Beneficial effects of targeting CCR5 in allograft recipients. Transplantation 2001; 72:1199-1205.
74. Hancock WW, Gao W, Csizmadia V, et al. Donor-derived IP-10 initiates development of acute allograft rejection. J Exp Med 2001; 193:975-980.
75. Hancock WW, Lu B, Gao W, et al. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med 2000; 192:1515-1520.
76. Magil AB, Tinckam K. Monocytes and peritubular capillary C4d deposition in acute renal allograft rejection. Kidney Int 2003; 63:1888-1893.
77. Wyburn KR, Jose MD, Wu H, et al. The role of macrophages in allograft rejection. Transplantation 2005; 80:1641-1647.
78. Jose MD, Ikezumi Y, van Rooijen N, et al. Macrophages act as effectors of tissue damage in acute renal allograft rejection. Transplantation 2003; 76:1015-1022.
79. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008; 214:199-210.
80. Duffield JS, Forbes SJ, Constandinou CM, et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 2005; 115:56-65.
81. Duffield JS. Macrophages and immunologic inflammation of the kidney. Semin Nephrol 2010; 30:234-254.
82. Diamond JR, Tilney NL, Frye J, et al. Progressive albuminuria and glomerulosclerosis in a rat model of chronic renal allograft rejection. Transplantation 1992; 54:710-716.
83. Hancock WH, Whitley WD, Tullius SG, et al. Cytokines, adhesion molecules, and the pathogenesis of chronic rejection of rat renal allografts. Transplantation 1993; 56:643-650.
84. Heemann UW, Tullius SG, Tamatami T, et al. Infiltration patterns of macrophages and lymphocytes in chronically rejecting rat kidney allografts. Transpl Int 1994; 7:349-355.
85. Floege J, Eitner F, Alpers CE. A new look at platelet-derived growth factor in renal disease. J Am Soc Nephrol 2008; 19:12-23.
86. Lee CG, Homer RJ, Zhu Z, et al. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J Exp Med 2001; 194:809-821.
87. Kolb M, Margetts PJ, Anthony DC, et al. Transient expression of IL-1beta induces acute lung injury and chronic repair leading to pulmonary fibrosis. J Clin Invest 2001; 107:1529-1536.
88. Wilson MS, Madala SK, Ramalingam TR, et al. Bleomycin and IL-1betamediated pulmonary fibrosis is IL-17A dependent. J Exp Med 2010; 207:535-552.
89. Burlingham WJ, Love RB, Jankowska-Gan E, et al. IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J Clin Invest 2007; 117:3498-3506.
90. Fan L, Benson HL, Vittal R, et al. Neutralizing IL-17 prevents obliterative bronchiolitis in murine orthotopic lung transplantation. Am J Transplant 2011; 11:911-922.
91. Wilson MS, Elnekave E, Mentink-Kane MM, et al. IL-13Ralpha2 and IL-10 coordinately suppress airway inflammation, airway-hyperreactivity, and fibrosis in mice. J Clin Invest 2007;117:2941-2951.
92. Fleming BD, Mosser DM. Regulatory macrophages: setting the threshold for therapy. Eur J Immunol 2011; 41:2498-2502.
93. Jose MD, Le MY, Atkins RC, Chadban SJ. Blockade of macrophage colonystimulating factor reduces macrophage proliferation and accumulation in renal allograft rejection. Am J Transplant 2003; 3:294-300.
94. Gladue RP, Brown MF, Zwillich SH. CCR1 antagonists: what have we learned from clinical trials. Curr Top Med Chem 2010; 10:1268-1277.
95. Sasaki M, Hasegawa H, Kohno M, et al. Antagonist of secondary lymphoidtissue chemokine (CCR ligand 21) prevents the development of chronic graft-versus-host disease in mice. J Immunol 2003; 170:588-596.
96. Zhao Q. Dual targeting of CCR2 and CCR5: therapeutic potential for immunologic and cardiovascular diseases. J Leukoc Biol 2010; 88:41-55.
97. Schneider MA, Bruhl H, Wechselberger A, et al. In vitro and in vivo properties of a dimeric bispecific single-chain antibody IgG-fusion protein for depletion of CCR2-target cells in mice. Eur J Immunol 2005; 35:987-995.
98. Ehrchen J, Steinmuller L, Barczyk K, et al. Glucocorticoids induce differentiation of a specifically activated, anti-inflammatory subtype of human monocytes. Blood 2007; 109:1265-1274.
99. Dayyani F, Belge KU, Frankenberger M, et al. Mechanism of glucocorticoidinduced depletion of human CD14-CD16-monocytes. J Leukoc Biol 2003; 74:33-39.
100. Turnquist HR, Raimondi G, Zahorchak AF, et al. Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4-T cells, but enrich for antigen-specific Foxp3-T regulatory cells and promote organ transplant tolerance. J Immunol 2007; 178:7018-7031.
101. Allison AC, Eugui EM. Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation 2005; 80 (2 Suppl):S181-S190.
102. Ballow M. The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J Allergy Clin Immunol 2011; 127:315-323.
103. Sutterwala FS, Noel GJ, Clynes R, Mosser DM. Selective suppression of interleukin-12 induction after macrophage receptor ligation. J Exp Med 1997; 185:1977-1985.
104. Sutterwala FS, Noel GJ, Salgame P,Mosser DM. Reversal of proinflammatory responses by ligating the macrophage Fcgamma receptor type I. J Exp Med 1998; 188:217-222.
105. Lucas M, Zhang X, Prasanna V, Mosser DM. ERK activation following macrophage FcgammaR ligation leads to chromatin modifications at the IL-10 locus. J Immunol 2005; 175:469-477.
106. Jiao J, Milwid JM, Yarmush ML, Parekkadan B. A mesenchymal stem cell potency assay. Methods Mol Biol 2011; 677:221-231.
107. Popp FC, Fillenberg B, Eggenhofer E, et al. Safety and feasibility of third-party multipotent adult progenitor cells for immunomodulation therapy after liver transplantation-a phase I study (MISOT-I). J Transl Med 2011; 9:124.
108. Ziai F, Nagano H, Kusaka M, et al. Renal allograft protection with losartan in Fisher->Lewis rats: hemodynamics, macrophages, and cytokines. Kidney Int 2000; 57:2618-2625.
109. Hutchinson JA, Riquelme P, Brem-Exner BG, et al. Transplant acceptanceinducing cells as an immune-conditioning therapy in renal transplantation. Transpl Int 2008; 21:728-741.
110. Hutchinson JA, Brem-Exner BG, Riquelme P, et al. A cell-based approach to the minimization of immunosuppression in renal transplantation. Transpl Int 2008; 21:742-754.
111. Hutchinson JA, Govert F, Riquelme P, et al. Administration of donor-derived transplant acceptance-inducing cells to the recipients of renal transplants from deceased donors is technically feasible. Clin Transplant 2009; 23:140-145.
112. Hutchinson JA, Roelen D, Riquelme P, et al. Preoperative treatment of a presensitized kidney transplant recipient with donor-derived transplant acceptance-inducing cells. Transpl Int 2008; 21:808-813.
113. Sagoo P, Perucha E, Sawitzki B, et al. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest 2010; 120:1848-1861.